Bausch Health Companies Inc
TSX:BHC

Watchlist Manager
Bausch Health Companies Inc Logo
Bausch Health Companies Inc
TSX:BHC
Watchlist
Price: 10.85 CAD 1.12%
Market Cap: 4B CAD
Have any thoughts about
Bausch Health Companies Inc?
Write Note

Net Margin
Bausch Health Companies Inc

-1.9%
Current
-5%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1.9%
=
Net Income
-178m
/
Revenue
9.5B

Net Margin Across Competitors

Country CA
Market Cap 4B CAD
Net Margin
-2%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 757B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 2.7T DKK
Net Margin
35%
Country US
Market Cap 350.9B USD
Net Margin
17%
Country US
Market Cap 252.8B USD
Net Margin
19%
Country CH
Market Cap 200.1B CHF
Net Margin
20%
Country UK
Market Cap 161.8B GBP
Net Margin
13%
Country CH
Market Cap 171.5B CHF
Net Margin
35%
Country US
Market Cap 150.9B USD
Net Margin
7%
No Stocks Found

Bausch Health Companies Inc
Glance View

Market Cap
4B CAD
Industry
Pharmaceuticals

Bausch Health Companies Inc. stands as a prominent player in the global healthcare arena, with its roots stretching back over a century. Originally known as Valeant Pharmaceuticals, the firm has undergone significant transformation, focusing on a diverse array of health-related products and innovations. The company operates primarily in three segments: Bausch + Lomb/International, Salix, and Ortho Dermatologics. Each of these divisions articulates its commitment to enhancing patients' lives through high-quality products that address the complex challenges of eye care, gastroenterology, and dermatology, respectively. The Bausch + Lomb sector, named after its foundational company, is recognized globally for its wealth of eye health products, including contact lenses, lens care products, and ophthalmic pharmaceuticals. This sector is integral to Bausch Health's revenue stream, contributing significantly through its diverse portfolio of over-the-counter and prescription offerings. At its core, Bausch Health has honed a business model centered around acquiring and developing specialty pharmaceuticals and health-enhancing technologies. Through strategic acquisitions, partnerships, and internal research, the company curates a vast pipeline of treatments and solutions. Revenue generation for Bausch Health is intrinsically linked to its global market footprint, operating in more than 100 countries. Sales teams across these regions work diligently to ensure that healthcare professionals and consumers alike have access to their products. Meanwhile, the company's commitment to innovation helps it remain responsive in rapidly evolving medical fields. The sales and marketing strategies are finely tuned to address regional disparities, leveraging local insights to maximize market penetration and bolster growth. Ultimately, Bausch Health Companies Inc. thrives by bridging high-quality health solutions with unmet global needs, seeking to leave a lasting impact on the lives it touches.

BHC Intrinsic Value
118.99 CAD
Undervaluation 91%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1.9%
=
Net Income
-178m
/
Revenue
9.5B
What is the Net Margin of Bausch Health Companies Inc?

Based on Bausch Health Companies Inc's most recent financial statements, the company has Net Margin of -1.9%.